Aradigm Corporation  

(Public, NASDAQ:ARDM)   Watch this stock  
Find more results for ARDM
+0.37 (7.91%)
Dec 12 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.75 - 5.20
52 week 0.78 - 5.68
Open 4.77
Vol / Avg. 0.00/178,941.00
Mkt cap 76.50M
P/E     -
Div/yield     -
EPS -0.98
Shares 15.15M
Beta 1.58
Inst. own 33%
Nov 2, 2017
Q3 2017 Aradigm Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -142.45% -16891.28%
Operating margin -108.06% -15395.90%
EBITD margin - -15332.82%
Return on average assets -114.71% -108.56%
Return on average equity - -273.38%
Employees 23 -
CDP Score - -


3929 Point Eden Way
HAYWARD, CA 94545-3720
United States - Map
+1-510-2659000 (Phone)
+1-510-2658878 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company's lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies. Its partnered programs under development include Inhaled Ciprofloxacin. It is also engaged in developing Smoking Cessation Therapy (ARD-1600 Inhaled Nicotine). Its lead development candidates are its formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)) that are delivered by inhalation for the management of infections associated with the severe respiratory diseases, such as cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (BE). Pulmaquin uses slow release liposomal formulation (Lipoquin) mixed with a small amount of ciprofloxacin dissolved in an aqueous medium.

Officers and directors

Virgil D. Thompson Independent Chairman of the Board
Age: 78
Bio & Compensation  - Reuters
Igor Gonda Ph.D. President, Chief Executive Officer, Director
Age: 68
Bio & Compensation  - Reuters
Nancy E. Pecota Chief Financial Officer, Vice President - Finance
Age: 54
Bio & Compensation  - Reuters
Juergen Froehlich Chief Medical Officer
Age: 58
Bio & Compensation  - Reuters
David Bell Director
Age: 61
Bio & Compensation  - Reuters
Frederick M. Hudson CPA Independent Director
Age: 71
Bio & Compensation  - Reuters
John M. Siebert Ph.D. Independent Director
Age: 77
Bio & Compensation  - Reuters